Published in Cancer Weekly, February 12th, 2008
"After a median follow-up of 4.7 years neither HR-negative nor HR-positive patients showed a benefit for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.